Neurocrine Biosciences | NBIX - Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
AbbVie USD -6.66B 3.39B 2026-03
Acadia Pharmaceuticals USD 1.25B 20.68M 2026-03
Agios Pharmaceuticals USD 1.11B 84M 2026-03
ALKERMES USD 1.75B 67.76M 2026-03
Alnylam Pharmaceuticals USD 1.08B 286.2M 2026-03
Amgen USD 9.19B 532M 2026-03
Biogen USD 18.65B 394.9M 2026-03
BioMarin Pharmaceutical USD 6.21B 125.11M 2026-03
Cytokinetics USD -826.57M 166.94M 2026-03
Enanta Pharmaceuticals USD 126.59M 61.87M 2025-12
Exelixis USD 1.94B 225.57M 2026-03
Gilead Sciences USD 23.52B 897M 2026-03
Halozyme Therapeutics USD 219.64M 170.82M 2026-03
Incyte USD 5.62B 455.37M 2026-03
Ionis Pharmaceuticals USD 491.41M 2.32M 2026-03
Nektar Therapeutics USD 89.83M 4.75M 2025-12
Neurocrine Biosciences USD 3.41B 154.3M 2026-03
Pfizer USD 90.1B 3.63B 2026-03
Prothena USD 312.62M 32.14M 2026-03
Regeneron Pharmaceuticals USD 31.42B 166.7M 2026-03
Repligen USD 2.11B 666K 2026-03
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sarepta Therapeutics USD 1.51B 364.48M 2026-03
Teva Pharmaceutical Industries USD 8.23B 314M 2026-03
Ultragenyx Pharmaceutical USD -236M 156M 2026-03
Vertex Pharmaceuticals USD 19.36B 696.1M 2026-03
Xoma USD 87.94M 15.5M 2025-09